INO Financial Facts
Total operating expenses: 32.74MResearch and development: 26.98M
See Full Income Statement
Accrued clinical trial expenses: 7.22M
Total liabilities and stockholders' equity: 194.55M
See Full Balance Sheet
Inovio Pharma (INO) Earnings
|
Expand Research on INO
| Next EPS Date | 8/12/26 | EPS Growth Rate | +59.0% |
|---|---|---|---|
| Average EPS % Beat Rate | 0.0% | Revenue Growth Rate | N/A |
| Average % Move 1-Wk after EPS | +5.9% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
8/12/26  |
Q226 | N/A | -$0.25 | N/A | N/A | N/A | N/A | N/A | N/A | ||
| 5/13/26 | Q126 | -$0.28 | $0.00 | -$0.28 | N/A | N/A | N/A |  | | Details | |
| 11/10/25 | Q325 | -$0.87 | $0.00 | -$0.87 | N/A | N/A | N/A | | | Details | |
| 8/12/25 |
Q225 | N/A | -$1.07 | N/A | N/A | N/A | N/A | N/A | N/A | ||
| 8/12/25 | Q225 | -$0.61 | $0.00 | -$0.61 | N/A | N/A | N/A | | | Details | |
| 5/13/25 | Q125 | -$0.51 | $0.00 | -$0.51 | N/A | N/A | N/A | | | Details | |
| 3/18/25 | Q424 | -$0.65 | $0.00 | -$0.65 | $120K | N/A | N/A | | | Details | |
| 11/14/24 | Q324 | -$0.89 | $0.00 | -$0.89 | N/A | N/A | N/A | | | Details |
